Title: Securing America’s Medical Supply Chain and Advancing the Production of Life Saving Medicines Act
Policy area: Foreign Trade and International Finance

Summary:
Securing America's Medical Supply Chain and Advancing the Production of Life Saving Medicines Act
This bill establishes the position of Chief Pharmaceutical and Medical Supply Chain Negotiator in the Office of the U.S. Trade Representative. The negotiator must conduct trade negotiations and enforce trade agreements related to pharmaceutical products and services and medical supply chains.

[Congressional Bills 116th Congress]
[From the U.S. Government Publishing Office]
[S. 3942 Introduced in Senate (IS)]

<DOC>






116th CONGRESS
  2d Session
                                S. 3942

  To establish the position of Chief Pharmaceutical and Medical Supply 
       Chain Negotiator in the Office of the United States Trade 
Representative, to be responsible for conducting trade negotiations and 
enforcing trade agreements related to acts, policies, and practices of 
  foreign governments that fail to appropriately reward United States 
    innovation with respect to pharmaceuticals, to advance domestic 
 production of life-saving medicines, and to secure the United States 
medical supply chain to eliminate reliance on foreign governments, and 
                          for other purposes.


_______________________________________________________________________


                   IN THE SENATE OF THE UNITED STATES

                             June 11, 2020

 Mrs. Loeffler introduced the following bill; which was read twice and 
                  referred to the Committee on Finance

_______________________________________________________________________

                                 A BILL


 
  To establish the position of Chief Pharmaceutical and Medical Supply 
       Chain Negotiator in the Office of the United States Trade 
Representative, to be responsible for conducting trade negotiations and 
enforcing trade agreements related to acts, policies, and practices of 
  foreign governments that fail to appropriately reward United States 
    innovation with respect to pharmaceuticals, to advance domestic 
 production of life-saving medicines, and to secure the United States 
medical supply chain to eliminate reliance on foreign governments, and 
                          for other purposes.

    Be it enacted by the Senate and House of Representatives of the 
United States of America in Congress assembled,

SECTION 1. SHORT TITLE.

    This Act may be cited as the ``Securing America's Medical Supply 
Chain and Advancing the Production of Life Saving Medicines Act''.

SEC. 2. CHIEF PHARMACEUTICAL AND MEDICAL SUPPLY CHAIN NEGOTIATOR.

    (a) In General.--Section 141 of the Trade Act of 1974 (19 U.S.C. 
2171) is amended--
            (1) in subsection (b)(2)--
                    (A) by striking ``and one Chief Innovation and 
                Intellectual Property Negotiator'' and inserting ``one 
                Chief Innovation and Intellectual Property Negotiator, 
                and one Chief Pharmaceutical and Medical Supply Chain 
                Negotiator'';
                    (B) by striking ``or the Chief Innovation and 
                Intellectual Property Negotiator'' and inserting ``the 
                Chief Innovation and Intellectual Property Negotiator, 
                or the Chief Pharmaceutical and Medical Supply Chain 
                Negotiator''; and
                    (C) by striking ``and the Chief Innovation and 
                Intellectual Property Negotiator'' and inserting ``the 
                Chief Innovation and Intellectual Property Negotiator, 
                and the Chief Pharmaceutical and Medical Supply Chain 
                Negotiator''; and
            (2) in subsection (c), by adding at the end the following 
        new paragraph:
    ``(7) The principal function of the Chief Pharmaceutical and 
Medical Supply Chain Negotiator shall be to conduct trade negotiations 
and to enforce trade agreements relating to United States 
pharmaceutical products and services and medical supply chains. The 
Chief Pharmaceutical and Medical Supply Chain Negotiator shall be a 
vigorous advocate on behalf of United States pharmaceutical and medical 
supply chain interests. The Chief Pharmaceutical and Medical Supply 
Chain Negotiator shall perform such other functions as the United 
States Trade Representative may direct.''.
    (b) Compensation.--Section 5314 of title 5, United States Code is 
amended by striking ``Chief Innovation and Intellectual Property 
Negotiator, Office of the United States Trade Representative.'' and 
inserting the following:
    ``Chief Innovation and Intellectual Property Negotiator, Office of 
the United States Trade Representative.
    ``Chief Pharmaceutical and Medical Supply Chain Negotiator, Office 
of the United States Trade Representative.''.
    (c) Report Required.--Not later than one year after the appointment 
of the first Chief Pharmaceutical and Medical Supply Chain Negotiator 
pursuant to paragraph (2) of section 141(b) of the Trade Act of 1974, 
as amended by subsection (a), and annually thereafter, the United 
States Trade Representative shall submit to the Committee on Finance of 
the Senate and the Committee on Ways and Means of the House of 
Representatives a report describing in detail--
            (1) enforcement actions taken by the Trade Representative 
        during the one-year period preceding the submission of the 
        report to ensure the protection of United States pharmaceutical 
        products and services and medical supply chains; and
            (2) other actions taken by the Trade Representative to 
        advance United States pharmaceutical products and services and 
        medical supply chain interests.
                                 <all>